Search research articles
Contact Us
Filters
Showing results (971-980 of 1,467) with videos related to
Page
of 147
Sort By:
Annals of the Rheumatic Diseases
|
August 13, 2014
Can we improve the performance and reporting of investigator-initiated clinical trials? Rheumatoid arthritis as an example
Robert B M Landewé, Josef S Smolen, Michael E Weinblatt, et al.
The Journal of Allergy and Clinical Immunology
|
October 1, 2025
A critical look at the lexicon, parameters, and limitations of asthma remission definitions
David J Jackson, Praveen Akuthota, Flavia Cecilia Lega Hoyte, et al.
Social Science Research
|
October 15, 2015
Life events, genetic susceptibility, and smoking among adolescents
Fred C Pampel, Jason D Boardman, Jonathan Daw, et al.
The Journal of Rheumatology
|
March 5, 2013
Longterm safety and efficacy of tocilizumab in patients with rheumatoid arthritis: a cumulative analysis of up to 4.6 years of exposure
Mark C Genovese, Andrea Rubbert-Roth, Josef S Smolen, et al.
Arthritis Research & Therapy
|
March 14, 2016
Nicotinic acetylcholine receptors modulate osteoclastogenesis
Peter Mandl, Silvia Hayer, Thomas Karonitsch, et al.
Arthritis & Rheumatology (Hoboken, N.J.)
|
November 19, 2016
Different Rating of Global Rheumatoid Arthritis Disease Activity in Rheumatoid Arthritis Patients With Multiple Morbidities
Helga Radner, Kazuki Yoshida, Sara Tedeschi, et al.
Annals of the Rheumatic Diseases
|
January 15, 2017
A randomised phase II study evaluating the efficacy and safety of subcutaneously administered ustekinumab and guselkumab in patients with active rheumatoid arthritis despite treatment with methotrexate
Josef S Smolen, Sandeep K Agarwal, Elena Ilivanova, et al.
Neurology and Therapy
|
September 18, 2024
Estimating the Economically Justifiable Price of Limited-Duration Treatment with Donanemab for Early Symptomatic Alzheimer's Disease in the United States
Malaz Boustani, Erin G Doty, Louis P Garrison, et al.
Rheumatology and Therapy
|
May 16, 2026
Olokizumab Improves Patient-Reported Outcomes in Patients with Active Rheumatoid Arthritis up to 106 Weeks (Results from the Open-Label Extension of Phase III Randomized Clinical Trials)
Roy M Fleischmann, Vibeke Strand, Eugen Feist, et al.
Arthritis Care & Research
|
January 22, 2020
Comparing the Patient-Reported Physical Function Outcome Measures in a Real-Life International Cohort of Patients With Psoriatic Arthritis
Ying Ying Leung, Ana-Maria Orbai, Maarten de Wit, et al.
Page
of 147
Search research articles
Search
Showing results (971-980 of 1,467) with videos related to
Sort By:
Page
of 147
Annals of the Rheumatic Diseases
|
August 13, 2014
Can we improve the performance and reporting of investigator-initiated clinical trials? Rheumatoid arthritis as an example
Robert B M Landewé, Josef S Smolen, Michael E Weinblatt, et al.
The Journal of Allergy and Clinical Immunology
|
October 1, 2025
A critical look at the lexicon, parameters, and limitations of asthma remission definitions
David J Jackson, Praveen Akuthota, Flavia Cecilia Lega Hoyte, et al.
Social Science Research
|
October 15, 2015
Life events, genetic susceptibility, and smoking among adolescents
Fred C Pampel, Jason D Boardman, Jonathan Daw, et al.
The Journal of Rheumatology
|
March 5, 2013
Longterm safety and efficacy of tocilizumab in patients with rheumatoid arthritis: a cumulative analysis of up to 4.6 years of exposure
Mark C Genovese, Andrea Rubbert-Roth, Josef S Smolen, et al.
Arthritis Research & Therapy
|
March 14, 2016
Nicotinic acetylcholine receptors modulate osteoclastogenesis
Peter Mandl, Silvia Hayer, Thomas Karonitsch, et al.
Arthritis & Rheumatology (Hoboken, N.J.)
|
November 19, 2016
Different Rating of Global Rheumatoid Arthritis Disease Activity in Rheumatoid Arthritis Patients With Multiple Morbidities
Helga Radner, Kazuki Yoshida, Sara Tedeschi, et al.
Annals of the Rheumatic Diseases
|
January 15, 2017
A randomised phase II study evaluating the efficacy and safety of subcutaneously administered ustekinumab and guselkumab in patients with active rheumatoid arthritis despite treatment with methotrexate
Josef S Smolen, Sandeep K Agarwal, Elena Ilivanova, et al.
Neurology and Therapy
|
September 18, 2024
Estimating the Economically Justifiable Price of Limited-Duration Treatment with Donanemab for Early Symptomatic Alzheimer's Disease in the United States
Malaz Boustani, Erin G Doty, Louis P Garrison, et al.
Rheumatology and Therapy
|
May 16, 2026
Olokizumab Improves Patient-Reported Outcomes in Patients with Active Rheumatoid Arthritis up to 106 Weeks (Results from the Open-Label Extension of Phase III Randomized Clinical Trials)
Roy M Fleischmann, Vibeke Strand, Eugen Feist, et al.
Arthritis Care & Research
|
January 22, 2020
Comparing the Patient-Reported Physical Function Outcome Measures in a Real-Life International Cohort of Patients With Psoriatic Arthritis
Ying Ying Leung, Ana-Maria Orbai, Maarten de Wit, et al.
Page
of 147